Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer

Authors:
Sushmita GordhandasGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York

Search for other papers by Sushmita Gordhandas in
Current site
Google Scholar
PubMedClose
 MD
,
William A. Zammarrelli IIIGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York

Search for other papers by William A. Zammarrelli III in
Current site
Google Scholar
PubMedClose
 MD
,
Eric V. Rios-DoriaGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York

Search for other papers by Eric V. Rios-Doria in
Current site
Google Scholar
PubMedClose
 MD
,
Angela K. GreenGynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
Department of Medicine, Weill Cornell Medical College, New York, New York

Search for other papers by Angela K. Green in
Current site
Google Scholar
PubMedClose
 MD
, and
Vicky MakkerGynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
Department of Medicine, Weill Cornell Medical College, New York, New York

Search for other papers by Vicky Makker in
Current site
Google Scholar
PubMedClose
 MD
View More View Less
Volume/Issue:
Volume 21: Issue 2
Online Publication Date:
Feb 2023
DOI:
https://doi.org/10.6004/jnccn.2022.7254
Restricted access

Endometrial cancer (EC) is the most common gynecologic malignancy, with worldwide increasing incidence and disease-associated mortality. Although most patients with EC are diagnosed with early-stage disease, systemic treatment options for patients with advanced or recurrent EC have historically been limited. EC-focused clinical trials and the ensuing therapeutic landscape have expanded since The Cancer Genome Atlas (TCGA) identified 4 distinct EC subgroups associated with differential survival. This endeavor revolutionized our understanding of the genomic characterization of EC as well as molecular drivers of this heterogeneous malignancy, leading to precision oncology approaches to therapeutics and advancement in treatment options. This review describes the current status of and recent advancements in therapeutic options for patients with advanced and recurrent EC. The NCCN Guidelines for Uterine Neoplasms provide detailed recommendations regarding the diagnosis, workup, and management of EC.

Submitted September 9, 2022; final revision received December 7, 2022; accepted for publication December 16, 2022.

Disclosures: Dr. Green has disclosed receiving institutional research support/grants from Mereo Biopharma and Eli Lilly. Dr. Makker has disclosed receiving research support/grants from Clovis, Merck, Eisai, Karyopharm, Faeth, Duality, and AstraZeneca; serving as a principal investigator for Clovis, Merck, Eisai, Karyopharm, Faeth, Duality, and AstraZeneca; and serving as an advisory board member for Eisai, Merck, Novartis, AstraZeneca, Clovis, Karyopharm, Faeth, Duality, and Morphosys. The remaining authors have disclosed that they have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.

Funding: Dr. Green and Dr. Makker are supported in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.

Correspondence: Vicky Makker, MD, Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. Email: makkerv@mskcc.org
  • Collapse
  • Expand
  • 1.

    Crosbie EJ, Kitson SJ, McAlpine JN, et al. Endometrial cancer. Lancet 2022;399:1412–1428.

  • 2.

    Gu B, Shang X, Yan M, et al. Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990–2019. Gynecol Oncol 2021;161:573–580.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Matsuo K, Mandelbaum RS, Matsuzaki S, et al. Ovarian conservation for young women with early-stage, low-grade endometrial cancer: a 2-step schema. Am J Obstet Gynecol 2021;224:574–584.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Clarke MA, Devesa SS, Harvey SV, et al. Hysterectomy-corrected uterine corpus cancer incidence trends and differences in relative survival reveal racial disparities and rising rates of nonendometrioid cancers. J Clin Oncol 2019;37:1895–1908.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Giaquinto AN, Broaddus RR, Jemal A, et al. The changing landscape of gynecologic cancer mortality in the United States. Obstet Gynecol 2022;139:440–442.

  • 6.

    Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol 2013;31:2607–2618.

  • 7.

    Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol 2016;34:4225–4230.

  • 8.

    Smith ES, Da Cruz Paula A, Cadoo KA, et al. Endometrial cancers in BRCA1 or BRCA2 germline mutation carriers: assessment of homologous recombination DNA repair defects. JCO Precis Oncol 2019;3:PO/19.00103.

    • Search Google Scholar
    • Export Citation
  • 9.

    Cadoo KA, Mandelker DL, Mukherjee S, et al. Understanding inherited risk in unselected newly diagnosed patients with endometrial cancer. JCO Precis Oncol 2019;3:18.00338.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67–73.

  • 11.

    Rios-Doria E. Molecular classification of endometrial carcinomas: a single institution review. Presented at the 2022 SGO Annual Meeting on Women’s Cancer; March 18–21, 2022; Phoenix, AZ.

    • Search Google Scholar
    • Export Citation
  • 12.

    Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). J Clin Oncol 2020;38:3841–3850.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Jooya ND, Ciccone MA, Brunette LL, et al. Population-level uptake of neoadjuvant chemotherapy for stage IVB endometrial cancer. Gynecol Oncol 2022;165:428–436.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Huang AB, Wu J, Chen L, et al. Neoadjuvant chemotherapy for advanced stage endometrial cancer: a systematic review. Gynecol Oncol Rep 2021;38:100887.

  • 15.

    Matei D, Filiaci V, Randall ME, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med 2019;380:2317–2326.

  • 16.

    de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol 2019;20:1273–1285.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Rubinstein M, Halpenny D, Makker V, et al. Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: a retrospective study of the Memorial Sloan Kettering Cancer Center experience. Gynecol Oncol Rep 2019;28:120–123.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Moore KN, Tian C, McMeekin DS, et al. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis. Cancer 2010;116:5407–5414.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Aghajanian C, Filiaci V, Dizon DS, et al. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol 2018;150:274–281.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Lorusso D, Ferrandina G, Colombo N, et al. Carboplatin-paclitaxel compared to carboplatin-paclitaxel-bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 – a randomized phase II trial. Gynecol Oncol 2019;155:406–412.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Makker V, Colombo N, Casado Herráez A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 2022;386:437–448.

  • 22.

    Abu-Rustum NR, Yashar CM, Bradley K, et al. NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms. Version 1.2022. Accessed September 1, 2022. To view the most recent version, visit https://www.nccn.org

    • Search Google Scholar
    • Export Citation
  • 23.

    Traina TA, Sabbatini P, Aghajanian C, et al. Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature. Gynecol Oncol 2004;95:235–241.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Thigpen JT, Buchsbaum HJ, Mangan C, et al. Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Cancer Treat Rep 1979;63:21–27.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Thigpen JT, Blessing JA, Beecham J, et al. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 1991;9:1962–1966.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Sutton GP, Blessing JA, DeMars LR, et al. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium. Gynecol Oncol 1996;63:25–27.

    • Search Google Scholar
    • Export Citation
  • 27.

    Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res 2020;26:3928–3935.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Tymon-Rosario J, Siegel ER, Bellone S, et al. Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu. Gynecol Oncol 2021;163:93–99.

    • Search Google Scholar
    • Export Citation
  • 29.

    Hasegawa K, Nishikawa T, Hirakawa A, et al. Efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma (STATICE trial, NCCH1615): a multicenter, phase II clinical trial. Ann Oncol 2021;32(Suppl 5):Abstract 813P.

    • Search Google Scholar
    • Export Citation
  • 30.

    Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:1–10.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Cortes-Ciriano I, Lee S, Park WY, et al. A molecular portrait of microsatellite instability across multiple cancers. Nat Commun 2017;8:15180.

  • 32.

    Kahn RM, Gordhandas S, Maddy BP, et al. Universal endometrial cancer tumor typing: how much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population? Cancer 2019;125:3172–3183.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Oaknin A, Tinker AV, Gilbert L, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol 2020;6:1766–1772.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Azad NS, Gray RJ, Overman MJ, et al. Nivolumab is effective in mismatch repair-deficient noncolorectal cancers: results from arm Z1D-A subprotocol of the NCI-MATCH (EAY131) study. J Clin Oncol 2020;38:214–222.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    O’Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol 2022;40:752–761.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Bellone S, Roque DM, Siegel ER, et al. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. Cancer 2022;128:1206–1218.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Bellone S, Roque DM, Siegel ER, et al. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Ann Oncol 2021;32:1045–1046.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Ott PA, Bang YJ, Berton-Rigaud D, et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol 2017;35:2535–2541.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Konstantinopoulos PA, Luo W, Liu JF, et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol 2019;37:2786–2794.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Antill Y, Kok PS, Robledo K, et al. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. a nonrandomized phase 2 clinical trial. J Immunother Cancer 2021;9:e002255.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol 2020;38:2981–2992.

  • 42.

    Singh M, Zaino RJ, Filiaci VJ, et al. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2007;106:325–333.

    • Search Google Scholar
    • Export Citation
  • 43.

    Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer 2007;17:964–978.

  • 44.

    Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:10–14.

    • Search Google Scholar
    • Export Citation
  • 45.

    Altman AD, Thompson J, Nelson G, et al. Use of aromatase inhibitors as first- and second-line medical therapy in patients with endometrial adenocarcinoma: a retrospective study. J Obstet Gynaecol Can 2012;34:664–672.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2011;29:2259–2265.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Vergote I, Powell MA, Teneriello MG, et al. Second-line lenvatinib in patients with recurrent endometrial cancer. Gynecol Oncol 2020;156:575–582.

  • 48.

    Rimel BJ. A randomized, phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer. Gynecol Oncol 2021;162(Suppl 1):S43–44.

    • Search Google Scholar
    • Export Citation
  • 49.

    Lheureux S, Matei D, Konstantinopoulos PA, et al. A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer. J Clin Oncol 2020;38(Suppl):Abstract 6010.

    • Search Google Scholar
    • Export Citation
  • 50.

    Giannone G, Tuninetti V, Ghisoni E, et al. Role of cyclin-dependent kinase inhibitors in endometrial cancer. Int J Mol Sci 2019;20:2353.

  • 51.

    Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016;375:2154–2164.

  • 52.

    Konstantinopoulos PA, Lee EK, Xiong N, et al. Phase 2, two-stage study of letrozole and abemaciclib in estrogen receptor (ER) positive recurrent or metastatic endometrial cancer (EC). Presented at the SGO 2022 Annual Meeting on Women’s Cancer; March 18–21, 2022; Phoenix, AZ.

    • Search Google Scholar
    • Export Citation
  • 53.

    Liu JF, Xiong N, Campos SM, et al. Phase II study of the WEE1 inhibitor adavosertib in recurrent uterine serous carcinoma. J Clin Oncol 2021;39:1531–1539.

  • 54.

    Rubinstein MM, Grisham RN, Cadoo K, et al. A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers. Gynecol Oncol 2021;160:71–76.

    • Search Google Scholar
    • Export Citation
  • 55.

    Vergote IB, Lund B, Peen U, et al. Phase 2 study of the exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies. Gynecol Oncol 2020;156:308–314.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Makker V, Perez-Fidalgo JA, Bergamini A, et al. Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): impact of subgroup analysis and molecular classification. J Clin Oncol 2022;40(Suppl):Abstract 5511.

    • Search Google Scholar
    • Export Citation
  • 57.

    Zammarrelli WA III, Kim SH, Da Cruz Paula A, et al. Risk stratification of stage I grade 3 endometrioid endometrial carcinoma in the era of molecular classification. JCO Precis Oncol 2022;6:e2200194.

    • Search Google Scholar
    • Export Citation
  • 58.

    van den Heerik ASVM, Horeweg N, Nout RA, et al. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer 2020;30:2002–2007.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Murali R, Delair DF, Bean SM, et al. Evolving roles of histologic evaluation and molecular/genomic profiling in the management of endometrial cancer. J Natl Compr Canc Netw 2018;16:201–209.

    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2023 by the National Comprehensive Cancer Network 2023
Page Numbers:
10
Article Category:
Review Article
Received:
09 Sep 2022
Accepted:
16 Dec 2022
Print Publication Date:
01 Feb 2023
Online Publication Date:
Feb 2023
Keywords:
advanced endometrial cancer; recurrent endometrial cancer; systemic therapy; targeted therapy; immunotherapy
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 4435 4434 431
PDF Downloads 3945 3945 431
EPUB Downloads 0 0 0